PhoreMost enters multi-target collaboration with Arvinas

Man using microscope in lab

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration.

Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration using Arvinas’s PROTAC Discovery Engine platform.

The platform is based on PhoreMost’s ‘Protein Interference’ (PROTEINi) technology, which probes the live cell environment for novel druggable targets linked to any chosen disease. SITESEEKER unmasks new druggable sites across the human proteome, linking them to useful therapeutic functions.

Dr Angela Cacace, Senior Vice President of Neuroscience & Platform Biology at Arvinas, said: “Identifying new protein binders is imperative for Arvinas as we expand the capabilities of our PROTAC platform. We are excited to begin this collaboration to leverage PhoreMost’s phenotypic screening platform and to make continued progress towards degrading undrugged targets across multiple complex diseases.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free